PATENT CLAIM ANALYSIS

Application Number: 16146762
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["424", "451000"]

Abstract:
The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation.

Claim (Index 105):
A method of treating a single ventricle heart disease (SVHD) patient with udenafil, or a pharmaceutically acceptable salt thereof, wherein the SVHD patient has undergone Fontan palliation and whose exercise capacity has been adversely affected due to a decline in the SVHD patient's myocardial function after the Fontan palliation, and wherein the SVHD patient is in need of treatment to improve the SVHD patient's exercise capacity, said method comprising:\n administering to the SVHD patient and whose exercise capacity has been adversely affected due to a decline in the SVHD patient's myocardial function after the Fontan palliation with an effective daily dose of udenafil, or a pharmaceutically acceptable salt thereof, to treat the SVHD patient.

Metadata:
- Claim Count in Document: 287.0
- Percentile: 97.0
- Lexical Diversity: 1.04
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15887523', '14788211', '14079548', '15671653', '14442711']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7149572799185838
- 35 USC 102 Novelty (BERT): 0.661180768815993
- Combined Prediction Score: 0.7095796288083248
- Mean Citation Score: 425.65413
- Max Citation Score: 788.03906
- Similarity Product: 602.7447020321405

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test